Richard C. Mulligan

52.1k citations

202 papers · 41.2k indexed · 20 hit papers · h-index 85

Genetics top 0.02%
- Virus-based gene therapy research 71
Immunology top 0.1%
- Immunotherapy and Immune Responses 32
- Immune Cell Function and Interaction 15
- T-cell and B-cell Immunology 15
Genetics top 0.05%
- Virus-based gene therapy research 71
Hematology top 0.1%
Molecular Biology top 0.05%
- RNA Interference and Gene Delivery 34
- CRISPR and Genetic Engineering 26
- Viral Infectious Diseases and Gene Expression in Insects 13
Oncology
- CAR-T cell therapy research 25

Co-authors: Daniel Ory Katja Brose Margaret A. Goodell David Baltimore G Paradis Richard S. Mann Didier Trono Philippe Gallay
Cited by: Genetics Immunology
Journals: Nature (12 papers)Science (12 papers)Cell (6 papers)
Partner nations: United States France Belgium

In The Last Decade

Richard C. Mulligan

200 papers receiving 39.8k citations

Hit Papers

15 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2005 Nature Biotechnology
2002 Science
1999 Nature
1997 Nature Medicine
1996 Proceedings of the National Academy of Sciences
1996 Science
1996 The Journal of Experimental Medicine
1996 Science
1994 Genes & Development
1994 Science
1994 Nature
1993 Science
1993 Proceedings of the National Academy of Sciences
1991 Science
1991 Cell
1988 Proceedings of the National Academy of Sciences
1986 Cell
1984 Cell
1983 Cell
1979 Nature

Peers

Countries citing papers authored by Richard C. Mulligan

Since Specialization

Citations

This map shows the geographic impact of Richard C. Mulligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Mulligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Mulligan more than expected).

Fields of papers citing papers by Richard C. Mulligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Mulligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Mulligan. The network helps show where Richard C. Mulligan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard C. Mulligan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard C. Mulligan Line = papers co-authored together Richard C. Mulligan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Attention-Deficit/Hyperactivity Disorder, Autistic Traits, and Substance Use Among Missouri Adolescents SHILAP Revista de lepidopterología ·Richard C. Mulligan,Angela M. Reiersen,Alexandre A. Todorov	2013	10
2	Detecting T-cell reactivity to whole cell vaccines OncoImmunology ·Ana Brusic,Ursula Hainz,Martha Wadleigh,Donna Neuberg,Mei Su,Christine Canning,Daniel J. DeAngelo,Richard M. Stone,Jeng-Shin Lee,Richard C. Mulligan,Jerome Ritz,Glenn Dranoff,Tetsuro Sasada,Catherine J. Wu	2012	14
3	Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome Journal of Clinical Investigation ·Karyn M. Austin,Mohan L. Gupta,Scott A. Coats,Asmin Tulpule,Gustavo Mostoslavsky,Alejandro B. Balazs,Richard C. Mulligan,George Q. Daley,David Pellman,Akiko Shimamura	2008	95
4	Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses in hematopoietic precursor cells Leukemia ·Aleksandra M. Glodek,Yi Le,Derek M. Dykxhoorn,Shin‐Young Park,Gustavo Mostoslavsky,Richard C. Mulligan,Judy Lieberman,Hilary E. Beggs,Marek Honczarenko,Leslie E. Silberstein	2007	53
5	Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer Proceedings of the National Academy of Sciences ·Gustavo Mostoslavsky,Attila J. Fabian,Seán Rooney,Frederick W. Alt,Richard C. Mulligan	2006	129
6	Exogenous control of mammalian gene expression via modulation of translational termination Nature Medicine ·George J. Murphy,Gustavo Mostoslavsky,Darrell N. Kotton,Richard C. Mulligan	2006	46
7	Exogenous control of mammalian gene expression through modulation of RNA self-cleavage Nature ·Laising Yen,Jennifer M. Svendsen,Jeng-Shin Lee,John T. Gray,Maxime Magnier,Takashi Baba,Robert J. D’Amato,Richard C. Mulligan	2004	210
8	Unexpectedly Efficient Homing Capacity of Purified Murine Hematopoietic Stem Cells Immunity ·Yumi Matsuzaki,Kentaro Kinjo,Richard C. Mulligan,Hideyuki Okano	2004	224
9	Gene therapy to target dendritic cells from blood to lymph nodes Gene Therapy ·Caroline Robert,Christoph Klein,Guijuan Cheng,Avi N Kogan,Richard C. Mulligan,Ulrich H. von Andrian,Thomas S. Kupper	2003	23
10	Glucose-induced Toxicity in Insulin-producing Pituitary Cells That Coexpress GLUT2 and Glucokinase Journal of Biological Chemistry ·Raquel N. Faradji,Evis Havari,Qian Chen,J. Patrick Gray,Keith Tornheim,Barbara E. Corkey,Richard C. Mulligan,Myra A. Lipes	2001	21
11	Expression of Bcl-XL Restores Cell Survival, but Not Proliferation and Effector Differentiation, in Cd28-Deficient T Lymphocytes The Journal of Experimental Medicine ·Astrid M. Dahl,Christoph Klein,Pietro G. Andres,Cheryl A. London,Michael P. Lodge,Richard C. Mulligan,Abul K. Abbas	2000	51
12	Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies Cancer Chemotherapy and Pharmacology ·William G. Nelson,Jonathan W. Simons,Bahar Mikhak,Ju-Fay Chang,Angelo M. De Marzo,Michael A. Carducci,Michael Kim,Christine E. Weber,Angelo A. Baccala,Marti A. Goeman,S Clift,Dale Ando,Hyam I. Levitsky,L. Cohen,Martin G. Sanda,Richard C. Mulligan,Alan W. Partin,H. Ballentine Carter,Steven Piantadosi,Fray F. Marshall	2000	62
13	Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. Journal of Clinical Investigation ·J.A. Huffman,William M. Hull,Glenn Dranoff,Richard C. Mulligan,J. A. Whitsett	1996	207
14	Gene Transfer as Cancer Therapy Advances in immunology ·Glenn Dranoff,Richard C. Mulligan	1995	110
15	A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse Molecular and Chemical Neuropathology ·Rob Willemsen,Victor L. J. Tybulewicz,Ellen Sidransky,William K. Eliason,Brian M. Martin,Mary E. LaMarca,A. J. J. Reuser,Michel L. Tremblay,H Westphal,Richard C. Mulligan,Edward I. Ginns	1995	34
16	Transgenic animals as tools for the study of fibrinolysis in vivo Journal of Internal Medicine ·Peter Carmeliet,Richard C. Mulligan,D Collen	1994	7
17	Biological Effects of Disruption of the Tissue‐Type Plasminogen Activator, Urokinase‐Type Plasminogen Activator, and Plasminogen Activator Inhibitor‐1 Genes in Mice^a Annals of the New York Academy of Sciences ·Peter Carmeliet,Ann Bouché,C. DE CLERCQ,Sara Janssen,Saskia Pollefeyt,Sabine Wyns,Richard C. Mulligan,D Collen	1994	54
18	Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. Journal of Clinical Investigation ·Peter Carmeliet,L Kieckens,Luc Schoonjans,Beverly Ream,An Van Nuffelen,George C. Prendergast,Michael D. Cole,Roderick Bronson,Désiré Collen,Richard C. Mulligan	1993	292
19	Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. Journal of Clinical Investigation ·Herbert A. Berger,Matthew P. Anderson,Richard J. Gregory,Simon Thompson,Paul W. Howard,Russell Maurer,Richard C. Mulligan,Alan E. Smith,Michael J. Welsh	1991	208
20	Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. The Journal of Experimental Medicine ·David A. Williams,K HSIEH,AD DeSilva,Richard C. Mulligan	1987	120

About Richard C. Mulligan

Richard C. Mulligan is a scholar working on Genetics, Immunology and Hematology, having authored 202 papers that have together received 41.2k indexed citations. Recurring topics across this work include Virus-based gene therapy research (71 papers), RNA Interference and Gene Delivery (34 papers), Immunotherapy and Immune Responses (32 papers), CRISPR and Genetic Engineering (26 papers), CAR-T cell therapy research (25 papers), Immune Cell Function and Interaction (15 papers), T-cell and B-cell Immunology (15 papers) and Viral Infectious Diseases and Gene Expression in Insects (13 papers). The work is most often cited by research in Genetics (11.9k citations), Immunology (8.6k citations) and Genetics (4.0k citations). Richard C. Mulligan has collaborated with scholars based in United States, France and Belgium. Frequent co-authors include Daniel Ory, Katja Brose, Margaret A. Goodell, David Baltimore, G Paradis, Richard S. Mann, Didier Trono, Philippe Gallay, Inder M. Verma and Luigi Naldini. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact